BioMarin Pharmaceutical Inc. recently agreed to a settlement with Par Pharmaceuticals surrounding Kuvan (sapropterin dihydrochloride) in which BioMarin will retain exclusive rights to the drug until Oct. 1, 2020.
The Food and Drug Administration (FDA) recently issued Merck a complete response letter for the company’s application for supplemental prescribing information on its labels for Januvia, Janumet and Janumet XR.
Patients suffering from multiple myeloma, a cancer of the blood cells, may soon get a new treatment option if officials from the U.S. Food and Drug Administration and the European Medicines Agency expand XGEVA to treat the illness.
Dupixent (dupilumab), an injectable drug from Sanofi and Regeneron Pharmaceuticals Inc. used to treat moderate to severe atopic dermatitis (AD), has been approved by the Food and Drug Administration (FDA).
A drug approved two years ago in the United States to treat schizophrenia is undergoing review in Europe, the final step before doctors there can prescribe it some 5 million patients suffering from the disorder.
Legislation designed to tie U.S. Postal Service retiree health care plans more closely with Medicare could needlessly saddle seniors with two insurance premiums, according to one health policy expert who has studied a bill introduced in the U.S. House of Representatives.
The Food and Drug Administration (FDA) has sent AstraZeneca a complete response letter (CRL) from the regulatory board in response to the development of sodium zirconium cyclosilicate, a drug designed to treat hyperkalaemia.